Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Endothelial oncogenic KRAS mutation drives the dynamics of microglia and macrophages in brain arteriovenous malformation
Hyejin Park, Jung-Eun Park, Bridger H. Freeman, Bosco Seong Kyu Yang, Shun-Ming Ting, Alexander K. Suh, Jude P.J. Savarraj, Shuning Huang, Jakob Körbelin, Huimahn Alex Choi, Sean P. Marrelli, Jaroslaw Aronowski, Peng Roc Chen, Eunhee Kim, Eun S. Park
Hyejin Park, Jung-Eun Park, Bridger H. Freeman, Bosco Seong Kyu Yang, Shun-Ming Ting, Alexander K. Suh, Jude P.J. Savarraj, Shuning Huang, Jakob Körbelin, Huimahn Alex Choi, Sean P. Marrelli, Jaroslaw Aronowski, Peng Roc Chen, Eunhee Kim, Eun S. Park
View: Text | PDF
Research Article Neuroscience Vascular biology

Endothelial oncogenic KRAS mutation drives the dynamics of microglia and macrophages in brain arteriovenous malformation

  • Text
  • PDF
Abstract

Mutation of KRAS in endothelial cells (KRAS-ECs) leads to intracerebral hemorrhage (ICH) in brain arteriovenous malformation (bAVM), resulting in severe disabilities or even death. However, it is unclear what causes this hemorrhagic conversion of bAVMs. Here, using a locally established, clinically relevant sporadic bAVM mouse model, created by overexpressing mutant KRAS (KRASG12V) in brain ECs, we demonstrate that KRAS-ECs act as trigger for activation of microglia (MG) and infiltration of macrophages (Mϕ). Using a 3-dimensional immunostaining approach with cleared human and mouse bAVM tissues, we demonstrate an abundance of MG/Mϕ around the bAVM nidus. The presence of MG/Mϕ was correlated to the blood-brain barrier leakage in bAVM areas. Time-lapsed intravital imaging in Cx3cr1-gfp;Ccr2-rfp reporter mice demonstrated the dynamic activation of MG and infiltration of Mϕ toward mutant KRASG12V–modified dysplastic vessels. Importantly, a time-course analysis showed that these activated MG and infiltrated Mϕ are present around the bAVMs prior to hemorrhagic conversion, and controlled depletion of MG/Mϕ reduced ICH incidence in bAVMs. Inhibition of MG/Mϕ with long-term minocycline treatment attenuated the incidence of ICHs around bAVMs. Our study indicates that MG/Mϕ are involved in destabilization of KRASG12V-induced bAVM, leading to hemorrhagic conversion/ICH. Thus, modulation of MG/Mϕ may reduce ICH risk in patients with bAVM.

Authors

Hyejin Park, Jung-Eun Park, Bridger H. Freeman, Bosco Seong Kyu Yang, Shun-Ming Ting, Alexander K. Suh, Jude P.J. Savarraj, Shuning Huang, Jakob Körbelin, Huimahn Alex Choi, Sean P. Marrelli, Jaroslaw Aronowski, Peng Roc Chen, Eunhee Kim, Eun S. Park

×

Figure 7

Posttreatment with minocycline attenuates ICH in KRASG12V/bEC mice.

Options: View larger image (or click on image) Download as PowerPoint
Posttreatment with minocycline attenuates ICH in KRASG12V/bEC mice.
(A) ...
(A) KRASG12V/bEC mice received minocycline for 4 weeks, every 2 days, starting from 6 weeks after AAV-BR1-KRASG12V injection, and the brains were analyzed at 10 weeks. (B and C) Representative images showing surface hemorrhages in KRASG12V/bEC mice treated with PBS or minocycline (B). D indicates dorsal view. V indicates ventral view. (C) Bar graphs quantifying the number of surface hemorrhages. Unpaired, 2-tailed t test. *P < 0.05. Each dot indicates the mean number of surface hemorrhages from an individual mouse (n = 6 per group). (D and E) Representative immunofluorescence images showing reduced Ter-119+ RBCs and Iba1+ MG/Mϕ in KRASG12V/bEC mice receiving posttreatment minocycline compared with PBS (D). Scale bar: 50 μm. (E) Bar graphs quantifying the number of Ter-119+ RBCs in the parenchyma. Unpaired, 2-tailed t test. **P < 0.01. Each dot indicates a randomly selected ROI (n = 30–34) from mice (n = 6–7 per group). (F) Representative immunofluorescence images showing reduced Iba1+ MG/Mϕ and restored VE-cadherin. Scale bar: 50 μm. (G and H) Bar graphs quantifying VE-cadherin+ fluorescence intensity (G) and CD31+ vessel area (H). **P < 0.01; ****P < 0.0001 by 1-way ANOVA with Tukey’s multiple comparisons test (G) or unpaired, 2-tailed t test (H). Each dot indicates a randomly selected ROI (G, n = 21–26; H, n = 27–30) obtained from mice (n = 6–7 per group). (I) Bar graphs quantifying numbers of Iba1+ MG/Mϕ for total, ramified, bushy, and amoeboid based on morphology assessment in the bAVM territory between KRASG12V/bEC mice treated with minocycline or PBS. Unpaired, 2-tailed t test. *P < 0.05, ***P < 0.001. Each dot indicates a randomly selected ROI (n = 19–20) obtained from mice (n = 6–7 per group). NS, not significant.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts